Breast Ductal Lavage and Fiberoptic Ductoscopy
Customize your policy alerts
Sign up for Aetna Policy 0517 alerts
Get alerted when Policy 0517 changes without checking for updates manually.
Monitor payer policy activity
Clinical policy governing the medical necessity and investigational status of breast ductal lavage and fiberoptic ductoscopy for Aetna members, including indications, limitations, and coding guidance.
No material clinical or coverage changes in this revision.
Coverage Criteria and Policy Position
inv-01: Medically necessary indications
Covered when ALL of the following are met
Examples of DL systems: Pro-Duct, ForeCYTE, MASCT, Halo (but screening indications are investigational).
inv-02: Experimental / Investigational
The following interventions are considered experimental and investigational because effectiveness has not been established:
inv-03: Coverage considerations
Coverage stance and considerations based on reported utility, reproducibility, and regulatory actions
Supported by feasibility and reproducibility studies and FDA commentary.
Evidence includes studies reporting high FD sensitivity and improved sensitivity with FD + cytology, and metabolomic/miRNA pilot studies.
Chen et al. 2019 proof-of-concept trial.
FDA warning letter and voluntary recall reported.
Use of ductal lavage (DL), nipple aspiration, or ductoscopy as a tool for population breast cancer screening is not supported by available evidence and is considered investigational/not covered. The policy notes that these interventions lack endorsement from federal public health agencies and professional organizations, and that data are insufficient to demonstrate clinical benefit as a screening test or as a routine risk‑assessment tool for asymptomatic women. Standard imaging and clinical evaluation remain the established approaches for breast cancer screening and risk assessment.
Nipple aspiration tests marketed as screening substitutes (for example, the ForeCYTE Breast Health test and related MASCT systems) are not supported by evidence and are considered investigational for breast cancer screening or risk assessment. The FDA has taken regulatory action relating to some commercial tests: a 2013 FDA warning letter cited misleading labeling for Atossa Genetics’ ForeCYTE test, and a voluntary recall was initiated in October 2013 to remove the ForeCYTE Breast Health Test from the market. These regulatory events may affect clinical availability and coverage.
The FDA has stated that the nipple aspirate test is no substitute for mammography. Unlike the cervical Pap smear, nipple aspirate testing lacks validated evidence demonstrating screening effectiveness, does not localize abnormal cells for targeted biopsy, and may produce a high proportion of samples with scant or no cellular material. Companies have reported that over 90% of nipple aspirate samples may contain very few or no cells, limiting diagnostic reliability and risking false reassurance or false positive/negative results.
Based on current evidence, DL, fiberoptic ductoscopy, and NAF-based tests used for breast cancer screening or routine risk assessment are considered not medically necessary / investigational. While DL and ductoscopy have limited roles in diagnostic contexts (see medically necessary indications), their use as screening modalities or for serial risk surveillance has not demonstrated sufficient sensitivity, reproducibility, or outcome benefit to support coverage outside of research or specified diagnostic indications.
Ductal lavage (DL) as a screening tool in asymptomatic women or for routine risk assessment is not supported due to technical and performance limitations documented in the literature: inconsistent nipple aspirate fluid (NAF) production, a high rate of inadequate cellular specimens, sub-optimal reproducibility of cytologic findings, and low sensitivity for detecting existing breast cancer. Studies report variable cannulation and cell-yield rates and fair to poor agreement for cytologic diagnosis over time, limiting the utility of DL for serial monitoring or population screening.
Coding and Billing Guidance
| 19030 | Injection procedure only for mammary ductogram or galactogram. |
| 77053 | Mammary ductogram or galactogram, single duct, radiological supervision and interpretation. |
| 77054 | Mammary ductogram or galactogram, multiple ducts, radiological supervision and interpretation. |
| 88112 | Cytopathology, selective cellular enhancement technique with interpretation (eg, liquid based slide preparation method), except cervical or vaginal. |
| 88161 | Cytopathology smears, any other source; preparation, screening and interpretation. |
| C50.011-C50.929 | Malignant neoplasm of breast [covered for known breast intraductal cancer when fiberoptic ductoscopy is used as a guide for resection only]. |
| N64.52 | Nipple discharge [non-lactational sporadic nipple discharge]. |
| N61.0-N61.1 | Inflammatory disorders of breast [non-lactational mastitis]. |
| N63.0-N63.42 | Unspecified lump in breast. |
| N64.3-N64.51, N64.53-N64.9 | Other disorders of breast. |
| T85.44x+ | Capsular contracture of breast implant. |
| Z12.39 | Encounter for other screening for malignant neoplasm of breast. |
| Z80.3 | Family history of malignant neoplasm of breast. |
| Z85.3 | Personal history of malignant neoplasm of breast. |
Provider Actions, Prior Authorization, and Documentation
Prior authorization verification
Prior authorization verification: This bulletin is informational about Aetna's position; specific prior authorization requirements or affected codes may vary by plan. Providers should verify prior authorization requirements with the member's plan before performing breast ductal lavage or fiberoptic ductoscopy and confirm any required CPT/HCPCS/ICD-10 codes and documentation needed for medical necessity review.
- Verify prior authorization requirements with the member's plan prior to service.
- Confirm the exact CPT/HCPCS/ICD-10 codes to be billed and whether they are subject to code-based prior authorization.
Prior authorization for ductoscopy
Prior authorization for ductoscopy: Prior authorization may be appropriate when ductoscopy is performed for evaluation of pathological (non-lactational) nipple discharge or to guide excision of known intraductal cancer. When required, approval should be supported by documentation of indication, prior noninvasive imaging, and cytology results as applicable.
- Ductoscopy for evaluation of pathological nipple discharge (e.g., spontaneous, unilateral, bloody or serous discharge).
- Ductoscopy used as an intraoperative guide for resection of known intraductal breast cancer (coverage limited to that indication).
Procedure and testing documentation
Required clinical and procedure documentation: When ductal lavage or fiberoptic ductoscopy is performed for a medically necessary indication, submit documentation that supports the indication and medical necessity. Documentation should be sufficient for retrospective review if requested.
- Indication for procedure (e.g., spontaneous, unilateral non-lactational nipple discharge; known intraductal cancer when ductoscopy is used to guide resection).
- Prior diagnostic workup including clinical exam, mammography and/or targeted breast ultrasound results.
- Cytology results when combined with ductoscopy (positive cytology when applicable).
- Procedure note describing technique, ducts examined, findings (visualized lesions, papillomas, masses), specimens collected, and operative guidance if ductoscopy was used during resection.
- For ductal lavage as an alternative to aspiration: documentation that nipple aspirate yield was inadequate for cytology.
- Follow-up plan and any pathology or tissue diagnosis obtained after the procedure.
Regulatory action may impact coverage
Regulatory action may impact coverage: Tests or devices removed from the market or subject to regulatory action (for example, the ForeCYTE Breast Health Test was voluntarily recalled after FDA enforcement action) may affect whether certain marketed ductal lavage products or test panels are considered acceptable for clinical use or covered by the plan. Verify that the specific test/device is marketed with appropriate regulatory status and provide supporting documentation when seeking coverage.
- If a named test or system (e.g., ForeCYTE, MASCT, Pro-Duct, Halo) has been recalled, withdrawn, or received an FDA warning, expect coverage determination to reflect that regulatory status.
- Provide current device/test labeling and regulatory status when requesting prior authorization or claim review.
Provider responsibilities and clinical judgment
Treating providers are responsible for medical advice and treatment; the information in this Clinical Policy Bulletin is intended to assist in administering plan benefits and is not a substitute for clinical judgment. Providers are responsible for ensuring that members receive appropriate clinical care and for supplying complete documentation to support medical necessity when requesting prior authorization or when claims are audited.
- Providers must counsel members on the risks, benefits, and alternatives to ductal lavage or ductoscopy.
- Submit complete medical records and test results to support any request for coverage or prior authorization.
- Clinical Policy Bulletins do not constitute guarantees of coverage — final determinations are made according to individual plan provisions.
Background and Rationale
Background: Breast ductal lavage (DL) and nipple aspirate fluid (NAF) collection are techniques intended to obtain epithelial cells from the lactiferous ducts for cytologic examination or biomarker testing. DL typically involves catheterization of ducts with saline infusion to wash and collect ductal epithelial cells, while NAF collection uses noninvasive suction devices (examples include the Halo and ForeCYTE systems). Although some specimen‑collection devices have received FDA 510(k) clearance for collection, evidence supporting clinical effectiveness of DL/NAF testing as screening tools is insufficient, and major guideline bodies and federal agencies do not recommend DL for breast cancer screening outside of research settings.
Molecular / Biomarker Notes and Research Findings
Line of Therapy / Use Context
inv-31: salvage
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.